ABDERRAHIM KHELIF; MARTINE FFRENCH; GILLES FOLLEA; BERTRAND COIFFIER; MARC DECHAVANNE; JEAN-JACQUES VIALA
To the editor: Acquired amegakaryocytic thrombocytopenic purpura is an uncommon but serious bone marrow failure, characterized by isolated thrombocytopenia with absent or decreased megakaryocytes in the marrow. Recently published data (1) suggest the possibility of an autoimmune pathogenesis. The management of this disease is not established. Various treatments, such as corticoids, androgens, lithium, vincristine, and mercaptopurine, have been ineffective (1, 2). The potential usefulness of antithymocyte globulin in the treatment of various bone marrow failure states has led us to consider this agent in the management of acquired amegakaryocytic thrombocytopenic purpura.
A 38-year-old man had a 2-month history of purpura
KHELIF A, FFRENCH M, FOLLEA G, COIFFIER B, DECHAVANNE M, VIALA J. Amegakaryocytic Thrombocytopenic Purpura Treated with Antithymocyte Globulin. Ann Intern Med. ;102:720. doi: 10.7326/0003-4819-102-5-720_1
Download citation file:
Published: Ann Intern Med. 1985;102(5):720.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use